Sanofi India Limited
Fundamental Score
Sanofi India Limited Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SANOFI across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (47.15%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (49.16%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (25.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Conservative Debt Levels (D/E: 0.03)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (336.47x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹2441.60 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (60.40%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Strong Institutional Confidence (FII+DII: 27.85%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
4 factors identified
Revenue Contraction (-9.27%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-8.10% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-0.44% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-0.44% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Financial Statements
Comprehensive financial data for Sanofi India Limited
About SANOFI
Business Overview
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Company Details
Key Leadership
Corporate Events
SANOFI Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sanofi India Limited (SANOFI)?
As of 30 Jan 2026, 01:39 pm IST, Sanofi India Limited (SANOFI) is currently trading at ₹4017.70. The stock has a market capitalization of ₹10.03K (Cr).
Is SANOFI share price Overvalued or Undervalued?
SANOFI is currently trading at a P/E ratio of 27.17x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Sanofi India Limited share price?
Key factors influencing SANOFI's price include its quarterly earnings growth (Sales Growth: -9.27%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sanofi India Limited a good stock for long-term investment?
Sanofi India Limited shows a 5-year Profit Growth of -0.44% and an ROE of 47.15%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.03 before investing.
How does Sanofi India Limited compare with its industry peers?
Sanofi India Limited competes with major peers in the Pharmaceuticals. Investors should compare SANOFI's P/E of 27.17x and ROE of 47.15% against the industry averages to determine its competitive standing.
What is the P/E ratio of SANOFI and what does it mean?
SANOFI has a P/E ratio of 27.17x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹27 for every ₹1 of annual earnings.
How is SANOFI performing according to Bull Run's analysis?
SANOFI has a Bull Run fundamental score of 49/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SANOFI belong to?
SANOFI operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sanofi India Limited.
What is Return on Equity (ROE) and why is it important for SANOFI?
SANOFI has an ROE of 47.15%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Sanofi India Limited generates profits from shareholders' equity.
How is SANOFI's debt-to-equity ratio and what does it indicate?
SANOFI has a debt-to-equity ratio of 0.03, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SANOFI's dividend yield and is it a good dividend stock?
SANOFI offers a dividend yield of 2.68%, which means you receive ₹2.68 annual dividend for every ₹100 invested.
How has SANOFI grown over the past 5 years?
SANOFI has achieved 5-year growth rates of: Sales Growth -8.10%, Profit Growth -0.44%, and EPS Growth -0.44%.
What is the promoter holding in SANOFI and why does it matter?
Promoters hold 60.40% of SANOFI shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SANOFI's market capitalization category?
SANOFI has a market capitalization of ₹10033 crores, placing it in the Mid-cap category.
How volatile is SANOFI stock?
SANOFI has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SANOFI?
SANOFI has a 52-week high of ₹N/A and low of ₹N/A.
What is SANOFI's operating profit margin trend?
SANOFI has a 5-year average Operating Profit Margin (OPM) of 25.01%, indicating the company's operational efficiency.
How is SANOFI's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -9.27% and YoY Profit Growth of 15.54%.
What is the institutional holding pattern in SANOFI?
SANOFI has FII holding of 5.57% and DII holding of 22.28%. Significant institutional holding often suggests professional confidence in the stock.